EcoDrugPlus

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSOMYG00000003367
Gene Symbol: PDGFRA
2 Cross references
197 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSOMYG00000026317
Gene Symbol: PDGFRB
1 Cross references
192 Possible Orthologues:

Polo-Like Kinase 4 (Drosophila)

Ensembl ID : ENSOMYG00000041771
Gene Symbol: PLK4
2 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSOMYG00000022893
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSOMYG00000047802
Gene Symbol: PARP3
1 Cross references
192 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSOMYG00000039908
Gene Symbol: PARP3
1 Cross references
194 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOMYG00000028680
Gene Symbol: KCNMA1
1 Cross references
226 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOMYG00000036791
Gene Symbol: KCNMA1
1 Cross references
234 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOMYG00000017987
Gene Symbol: KCNMA1
1 Cross references
229 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOMYG00000012448
Gene Symbol: KCNMA1
1 Cross references
235 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSOMYG00000001766
Gene Symbol: KCNK3A
1 Cross references
196 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSOMYG00000039686
Gene Symbol: KCNK3A
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).